Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only

UK prescribing information ROI prescribing information UK SmPC ROI SmPC Report an adverse event

^▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events.

Resources

Back PDFs

Videos

Patient perspectives (1/5): Diagnosis

Patient perspectives (2/5): Journey to PEMAZYRE

Patient perspectives (3/5): Starting PEMAZYRE treatment

Patient perspectives (4/5): Experience with PEMAZYRE

Patient perspectives (5/5): Reflections on treatment

Privacy Policy Cookie Policy Terms of Use If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/
Marketing authorisation holder:
United Kingdom
Incyte Biosciences UK Ltd,
First Floor Q1, The Square,
Randalls Way, Leatherhead,
KT22 7TW, UK

Republic of Ireland
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25,
1105 BP Amsterdam, Netherlands

UNITED KINGDOM
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte by calling 00‑800‑0002‑7423.

REPUBLIC OF IRELAND
Adverse events should be reported.Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie. Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800‑456‑748.

^▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.

IE/PEMA/P/25/0012
Date of preparation: April 2025
Developed and funded by Incyte Biosciences International Sàrl.
© 2025, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.

Resources

Videos

External link disclaimer

Caution

Want to be kept up to date with the latest news in oncology? Complete this quick form to receive relevant information from Incyte